Nurix Therapeutics Appoints New CMO, Adds Director
Ticker: NRIX · Form: 8-K · Filed: Oct 16, 2024 · CIK: 1549595
Sentiment: neutral
Topics: management-change, board-appointment, executive-compensation
Related Tickers: NRIX
TL;DR
Nurix beefs up leadership with a new CMO and board member.
AI Summary
Nurix Therapeutics, Inc. announced on October 15, 2024, the appointment of Dr. Robert L. Kirk as Chief Medical Officer and the election of Ms. Jennifer L. D. Good to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers. This filing follows a period of significant activity for the clinical-stage biopharmaceutical company.
Why It Matters
The appointment of a new Chief Medical Officer and a new board member can signal strategic shifts or a strengthening of leadership within the company, potentially impacting future drug development and corporate governance.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can indicate internal shifts that may affect company strategy and performance, warranting closer observation.
Key Players & Entities
- Nurix Therapeutics, Inc. (company) — Registrant
- Dr. Robert L. Kirk (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. D. Good (person) — Elected to Board of Directors
- October 15, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Nurix Therapeutics?
Dr. Robert L. Kirk has been appointed as the new Chief Medical Officer of Nurix Therapeutics.
Who has been elected to the Board of Directors at Nurix Therapeutics?
Ms. Jennifer L. D. Good has been elected to the Board of Directors at Nurix Therapeutics.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing is October 15, 2024.
What other information is disclosed regarding executive officers in this filing?
The filing also discloses compensatory arrangements for certain named executive officers.
What is the state of incorporation for Nurix Therapeutics, Inc.?
Nurix Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 991 words · 4 min read · ~3 pages · Grade level 11.7 · Accepted 2024-10-16 16:41:07
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share NRIX Nasdaq Global
- $50,000 — will receive a pro rata portion of the $50,000 annual retainer for service as a direct
- $5,000 — 30, 2024, and a pro rata portion of the $5,000 annual retainer for service as a member
Filing Documents
- nrix-20241015.htm (8-K) — 31KB
- a241016prfornewboardmember.htm (EX-99.1) — 14KB
- image_0.jpg (GRAPHIC) — 7KB
- 0001549595-24-000138.txt ( ) — 192KB
- nrix-20241015.xsd (EX-101.SCH) — 2KB
- nrix-20241015_lab.xml (EX-101.LAB) — 24KB
- nrix-20241015_pre.xml (EX-101.PRE) — 14KB
- nrix-20241015_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed herewith and this list is intended to constitute the exhibit index: Exhibit No. Exhibit Title or Description 99.1 Press Release dated October 16, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NURIX THERAPEUTICS, INC. Date: October 16, 2024 By: /s/ Christine Ring Christine Ring, Ph.D., J.D. Chief Legal Officer and Secretary 3